Skip to main content
SpringerLink
Log in

Formulation development and characterization of cellulose/ polyacrylic acid – based polymers on the release of celecoxib from extended release tablets

  • ORIGINAL PAPER
  • Published:
Journal of Polymer Research Aims and scope Submit manuscript

Abstract

The study was aimed to formulate an extended release matrix tablets of celecoxib and to investigate the influence of different types and concentration of polymers on release of drug. Six formulations namely F1 – F6 were manually designed using different proportions of polymers. The matrix tablets formulations (F1 – F5) were composed of using different polymers such as, hydroxypropyl methylcellulose (HPMC-K4M), carboxymethyl cellulose (CMC), ethylcellulose (EC-10 cps) and Carbopol-940, whereas plain tablets formulation (F6) without polymer contained microcrystalline cellulose (MCC), lactose monohydrate, sodium lauryl sulfate (SLS) and polyvinylpyrrolidone (PVP-K30). The MCC, SLS and PVP-K30 were used in a fixed quantity in all formulations except F6 i.e. 20.7%, 6.7%, and 2%, respectively. Multiple point dissolution was performed in phosphate buffer of pH 7.4. Dissolution profiles indicated that formulations F2 and F3 extended the drug release up to the desired time period of 12 h. DD Solver (an add-in software for MS Excel) was used to analyze the dissolution profile data for drug release kinetics such as first order, Zero-order, Higuchi and Korsmeyer–Peppas models. However, formulation (F3) containing HPMC – K4M as a matrix former showed concentration-independent drug release as highest linearity was observed when zero-order model was applied (R2 = 0.933). Release mechanism of formulations F3 was super case-II transport. Fourier transform infrared spectroscopy (FTIR) was used to assess the drug polymers compatibility and no drug– excipients interaction was found. The present study accomplished that ethylcellulose and HPMC can be used successfully to develop an extended release matrix tablet formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Nasiri MI, Yousuf RI, Shoaib MH, Fayyaz M, Qazi F, Ahmed K (2016) Investigation on release of highly water soluble drug from matrix-coated pellets prepared by extrusion–spheronization technique. J Coat Technol Res 13(2):333–344

    Article  CAS  Google Scholar 

  2. James HP, John R, Alex A, Anoop K (2014) Smart polymers for the controlled delivery of drugs – a concise overview. Acta Pharm Sin B 4(2):120–127

    Article  Google Scholar 

  3. Siepmann J, Kranz H, Bodmeier R, Peppas N (1999) HPMC-matrices for controlled drug delivery: a new model combining diffusion, swelling, and dissolution mechanisms and predicting the release kinetics. Pharm Res 16(11):1748–1756

    Article  CAS  Google Scholar 

  4. Reynolds TD, Gehrke SH, Hussain AS, Shenouda LS (1998) Polymer Erosion and Drug Release Characterization of Hydroxypropyl Methylcellulose Matrices. J Pharma Sci 87(9):1115–1123

    Article  CAS  Google Scholar 

  5. Barakat NS, Elbagory IM, Almurshedi AS (2009) Controlled-release carbamazepine matrix granules and tablets comprising lipophilic and hydrophilic components. Drug Deliv 16(1):57–65

    Article  CAS  Google Scholar 

  6. Perez-Marcos B, Iglesias R, Gomez-Amoza J, Martinez-Pacheco R, Souto C, Concheiro A (1991) Mechanical and drug-release properties of atenolol-Carbomer hydrophilic matrix tablets. J Control Release 17(3):267–276

    Article  CAS  Google Scholar 

  7. Aulton M (2002) Taylor K. Pharmaceutics-The science of dosage form design.Churchill Livingstone, London

    Google Scholar 

  8. Agrawal S, Soni N, Jain NK, Agrawal G (2012). Int J Pharma Sci Res 3(7):2325

    CAS  Google Scholar 

  9. Tive L (2000) Celecoxib clinical profile. Rheumatology 39:21–28

    Article  CAS  Google Scholar 

  10. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 297(2):638–645

    CAS  PubMed  Google Scholar 

  11. Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein KE (2012) Celecoxib pathways. Pharmacogenet Genom 22(4):310–318

    Article  CAS  Google Scholar 

  12. USP35-NF30 (2013) The United States Pharmacopeial Convention, USA

  13. Mathur N, Kumar R, Tiwari K, Singh S, Fatima N (2015). World J Pharm Pharmaceut Sci 4(7):976–984

    CAS  Google Scholar 

  14. Saleem A, Nasiri MI, Zaheer K, Anwer S, Ali T, Sarwar H, Azeem M, Naqvi SS (2018). Lat Am J Pharm 37(12):2476–2481

    Google Scholar 

  15. Primo FT, Fröhlich P (2005). Lat Am J Pharm 24(3):421

    CAS  Google Scholar 

  16. Saha R, Sajeev C, Jadhav P, Patil S, Srinivasan N (2002) Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography. J Pharmaceut Biomed Anal 28(3–4):741–751

    Article  CAS  Google Scholar 

  17. Chandran S, Ravi P, Saha RN (2006) Yakugaku zasshi 126(7):505-514

  18. Biswas BK, Islam MS, Begum F, Rouf ASS (2008). Dhaka Univ J Pharma Sci 7(1):39–45

    Article  Google Scholar 

  19. Wise DL (2000) Handbook of pharmaceutical controlled release technology. CRC press

  20. Caço AI, Varanda F, Pratas de Melo MJ, Dias AM, Dohrn R, Marrucho IM (2008). Ind Eng Chem Res 47(21):8083–8089

    Article  Google Scholar 

  21. Alekseev K, Blynskaya E, Tikhonova N, Alekseev V, Uvarov N, Chernova O (2012) Polymers in the formulation of drug dosage forms with modified release. Russ J Gen Chem 82(3):564–571

    Article  CAS  Google Scholar 

  22. Iwata M, Ueda H (1996) Dissolution Properties of Glibenclamide in Combinations with Polyvinylpyrrolidone. Drug Dev Ind Pharm 22(11):1161–1165

    Article  CAS  Google Scholar 

  23. Chowdary KPR, Ramesh KVR (1995). Indian drugs 32(10):477–483

    CAS  Google Scholar 

  24. Enzian G (1972). Pharm Acta Helv 47:321–363 [in French]

    Google Scholar 

  25. Wallace CJT, Shangraw RF (1983). Pharm Technol 7(9):94–104

    CAS  Google Scholar 

  26. Omray A, Omray P (1986). Indian J Pharm Sci 48:20–22

    Google Scholar 

  27. Lachman L, Lieberman HA, Kanig JL (1976) The theory and practice of industrial pharmacy: Lea & Febiger Philadelphia

  28. Raza M, Naqvi SBS, Nasiri MI, Ali T, Zaheer K, Saleem A, Sarwar H, Azeem M (2018). RADS J Pharm Pharmaceut Sci 6(2):152–156

    CAS  Google Scholar 

  29. Teja SB, Patil SP, Shete G, Patel S, Bansal AK (2016). J Excipients Food Chem 4(3):1048

    Google Scholar 

  30. Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK (2005) Molecular pharmaceutics 2(5): 384-391

  31. Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB (2003) Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech 4(3):18–23

    Article  Google Scholar 

  32. Kaur D, Raina A, Singh N (2014). Int J Pharm Pharm Sci 6:434–440

    CAS  Google Scholar 

  33. Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, Xie S (2010) DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles. The AAPS J 12(3):263–271

    Article  Google Scholar 

  34. Nasiri MI, Yousuf RI, Shoaib MH, Zaheer K, Ali T, Ahmed K, Qazia F, Anwer S (2019). J Coat Technol Res 13(2):333–344

    Article  Google Scholar 

  35. Qazi F, Shoaib MH, Yousuf RI, Nasiri MI, Ahmed K, Ahmad M (2017) Lipids bearing extruded-spheronized pellets for extended release of poorly soluble antiemetic agent—Meclizine HCl. Lipids Health Dis 16(1):75

    Article  Google Scholar 

  36. Mostafavi A, Emami J, Varshosaz J, Davies NM, Rezazadeh M (2011) Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: Pharmacokinetic characterization in healthy human volunteers. Int J Pharm 409(1–2):128–136

    Article  CAS  Google Scholar 

Download references

Acknowledgments

Authors are thankful to M/S Genome Pharmaceuticals Limited Hattar, Pakistan for providing active pharmaceutical ingredient. Authors also thankful to the Department of pharmaceutics, Riphah International University, Islamabad, Pakistan, for providing laboratory facilities, equipment, and their valuable guidance, support, and cooperation.

Funding

This work was not supported by any funding awarding body. It was purely author’s funded project.

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, Riphah International University, Islamabad, Pakistan

    Muhammad Umair Saleem, Shahiq-uz Zaman & Nouman Khan

  2. Department of Pharmaceutics, Hamdard Institute of Pharmaceutical Sciences, Hamdard University, Campus, Islamabad, Pakistan

    Muhammad Umair Saleem, Muhammad Iqbal Nasiri & Muhammad Azeem

Authors
  1. Muhammad Umair Saleem
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Muhammad Iqbal Nasiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shahiq-uz Zaman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nouman Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammad Azeem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Iqbal Nasiri.

Ethics declarations

Conflict of interest

The authors declared no conflict of interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saleem, M.U., Nasiri, M.I., Zaman, Su. et al. Formulation development and characterization of cellulose/ polyacrylic acid – based polymers on the release of celecoxib from extended release tablets. J Polym Res 27, 234 (2020). https://doi.org/10.1007/s10965-020-02201-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10965-020-02201-6

Keywords

Search

Navigation